Antiobesity and Cholesterol-Lowering Effects of Bifidobacteria animalis DY-64 in Rats Fed a High-Fat/High-Cholesterol Diet

Seong-Ho Choi,†, Myung-Yul Lee, Deok-Young Jhon, Yang-II Choi, and Jae-Joon Lee*

Department of Food and Nutrition, Chosun University, Gwangju 500-759, Korea
1Department of Animal Science, Chungbuk National University, Cheongju 361-763, Korea
2Department of Animal Science, Texas A&M University, College Station, TX 77843, USA
3Department of Food and Nutrition, Chonnam National University, Gwangju 550-757, Korea

Abstract

The present study was carried out to investigate the antiobesity and hypocholesterolemic effects of Bifidobacteria animalis DY-64 (B. animalis DY-64), a lactic acid bacterium isolated from the human intestine, in rats fed a high-fat/high-cholesterol diet for 4 weeks. Forty male Sprague-Dawley rats were divided into four groups and fed either a normal (N) or high-fat/high-cholesterol (HFC) diet without or with oral administration of B. animalis DY-64 (N-BA, HFC-BA). The gain in body weight, and liver and adipose tissue weights of the HFC group were heavier than that of the HFC-BA group. Serum total cholesterol (TC), LDL-cholesterol, and leptin levels of the HFC group, which were significantly elevated compared to those of the N group, dropped by 19, 18, 21, and 13% in the HFC-BA group, respectively, whereas the serum HDL-cholesterol level markedly increased. However, serum TG, LDL-cholesterol, HDL-cholesterol, and leptin levels were not significantly different among the N groups (N, N-BA) with or without B. animalis DY-64 administration. TC and TG levels of the liver as well as the TG level of the adipose tissue were significantly reduced in the HFC-BA group. In addition, HR-LPL activity in adipose tissue was also lower in the HFC-BA group than in the HFC group. These results suggest that B. animalis DY-64 isolated from the human intestine exerts hypocholesterolemic effects by reducing serum and liver cholesterol levels and plays a role in the prevention of obesity induced by HFC diet.

Key words: Bifidobacteria animalis DY-64, high-fat/high-cholesterol diet, obesity, cholesterol, rat

Introduction

Obesity, a condition in which an abnormally large amount of fat is stored as adipose tissue, is becoming a global epidemic as well as a major contributor to the increased incidence of serious chronic diseases such as type 2 diabetes, cardiovascular diseases, hepatic and skeletal muscle insulin resistance, hypertension, arthritis, and certain forms of cancer (Haslam, 2005). In general, it is known that a high-fat diet contributes to obesity, and long-term intake evokes significant increases in abdominal fat weights in mammals (Iwashita et al., 2002). Since obesity and cardiovascular disease are prevalent health problems worldwide, researchers have become interested in the effectiveness of different foods in reducing body weight and improving other risk factors (Nettleton et al., 2009; Nicolosi et al., 2001).

Probiotics such as lactic acid bacteria (LAB) are known to exert various physiological functions in humans. Recent studies have reported the preventive effects of probiotics on obesity and cardiovascular diseases such as atherosclerosis, coronary heart diseases, and stroke (An et al., 2011; Xiao et al., 2010). Among commensal bacteria, Bifidobacterium, which belongs to Actinomycetes and is also a kind of LAB, is one of the most prolific probiotics in the mammalian gut (An et al., 2011; Yin et al., 2010). Bifidobacterium and Lactobacillus have been used in fermented foods for several centuries without any adverse effects (Fuller, 1992), and they are classified as Generally Recognized as Safe (GRAS) due to their long history of safe use, particularly in dairy foods (Donohu, 2006). Xiao et al (2003) previously observed that a strain of Bifidobacterium longum exhibited more significant effects in lowering serum total cholesterol than a mixed culture of...
Streptococcus thermophilus and Lactobacillus delbrueckii subspecies in both rats and humans. Furthermore, several studies have reported antiobesity effects of bacterial strains such as Bifidobacterium and Lactobacillus (An et al., 2011; Yin et al., 2010). An et al (2011) found that Bifidobacterium spp. has hypcholesterolemic and hypotriacylglycerolemic effects in high fat diet-induced obese rats. Further, Bifidobacterium spp. has been observed to reduce body weight in rats. Thus, Bifidobacterium appears to improve lipid metabolism and body fat deposition.

The antiobesity and hypcholesterolemic effects of LAB have become an area of great interest and controversy for many researchers. In this study, we evaluated the effects of LAB on obesity based on body weight, feed intake, serum leptin and lipid levels, and adipose tissue LPL activity in high-fat/high-cholesterol diet-induced rats. It is known that high-fat/high-cholesterol diet-induced animal models can develop obesity, hyperglycemia, hypercholesterolemia, and hyperinsulinemia (Garrow et al., 1992).

Material and Methods

Animal and diets

A total of 32 male Sprague-Dawley rats, initial body weight 150 g, were purchased from Central Lab Animal Inc. (Korea) at 4 wk of age. Rats were housed in individual stainless steel cages under controlled conditions at temperatures between 21 and 23°C with a 12:12 h light-dark cycle (08:00-20:00 h light). Rats were provided unrestricted access to rat chow and water in our animal facility for at least 2 wk before the experiments in order to minimize the effects of changes in feeding schedules and diurnal rhythms on data variability. As shown in Table 1, four experimental groups were normal diet (N), normal diet with high-fat diet (HFC), and high-fat/high-cholesterol diet with N-BA, D-BA, respectively (Rosenfeld, 1989). An enzyme-linked immunosorbent assay kit (Linco Research, USA) was used to determine serum leptin levels, according to the manufacturer’s instructions. The absorbance was measured using a microplate spectrophotometer (Biorad, USA).

Measurement of organ weights as well as serum lipid and leptin levels

At the end of the experimental period, experimental diets were withheld for 12 h. On the day of an experiment, rats were killed by decapitation after light anesthesia in a CO₂-saturated chamber, and blood samples from each rat were collected into tubes. Sera were separated from blood by centrifugation at 3,000 rpm for 20 min. After bleeding, liver, epididymal, and mesenteric adipose tissues were quickly excised, weighed, and frozen in liquid nitrogen for subsequent analysis. Serum concentrations of triglyceride (TG), total cholesterol (TC), and high-density lipoprotein cholesterol (HDL-cholesterol) were calculated using a commercial assay kit (Fuji Dri-Chem 3500s, Fujifilm, Japan). Serum low-density lipoprotein cholesterol (LDL-cholesterol) was calculated by the Friedwald formula (Friedwald et al., 1972) {total cholesterol − (HDL-cholesterol − TG/5)}. The atherogenic index (AI) and cardiac risk factor (CRF) were calculated using the following formulas: {{total cholesterol − HDL-cholesterol)/ HDL-cholesterol} and {total-cholesterol/HDL-cholesterol}, respectively (Rosenfeld, 1989). An enzyme-linked immunosorbent assay kit (Linco Research, USA) was used to determine serum leptin levels, according to the manufacturer’s instructions. The absorbance was measured using a microplate spectrophotometer (Biorad, USA).
Adipose tissues were measured by the methods of Biggs et al. (1975), and Zlatkis and Zak (1969), respectively.

Assay of lipoprotein lipase (LPL) activity
LPL activity was measured according to the method of Nilsson-Ehle and Schotz (1976). Dissected epididymal and mesenteric adipose tissues were minced into 5-10 mg fragments totaling 50 mg and frozen in liquid nitrogen. To assess heparin-releasable LPL (HR-LPL) activity, tissue fragments were defrosted in 0.4 mL of Medium 199 (Gibco BRL, USA) containing 1% bovine serum albumin and 50 U/mL of heparin, followed by incubation for 45 min at 24°C with shaking. LPL activity in the heparin elute was measured using the glycerol stabilized 3H-triolein emulsion as substrate. One unit of LPL activity is defined as the release of 1 µmol of free fatty acid in 1 h.

Statistical analysis
All data were expressed as the means±standard error of mean (SEM). Statistical analysis was performed using ANOVA followed by Tukey’s test. Student’s t-test was used to confirm comparisons between the groups. Statistical significance was considered to be at the p<0.05 level.

Results and Discussion

Effects of BA on body weight gain, feed intake, and feed efficiency ratio
All rats appeared to be healthy, showing no pathological signs or abnormalities during the administration period. Daily body weight gain, feed intake, and feed efficiency ratio (FER) are shown in Table 2. In general, changes in body weight reflect the overall effects of antiobesity candidate materials in vivo. Body weight gain, feed intake, and FER did not differ among the N groups (N, N-BA), whereas the HFC group had slightly exhibited higher body weight. The HCF group had showed a +22% increase in body weight compared to the N group. In contrast, the HFC-BA group had showed a significantly lower body weight gain of -17% compared to the HCF group. This reduction of body weight of the HFC-BA group was comparable to that of the N group, suggesting that B. animalis DY-64 administration was able to retard increases in body weight. Feed intake of the HCF group was lower than that of the N group, whereas the HFC group had slightly exhibited higher feed intake.

Table 2. Effects of B. animalis DY-64 administration on body weight gain, feed intake and feed efficiency ratio, liver and adipose tissue weights in rats fed high-fat/high-cholesterol diet

<table>
<thead>
<tr>
<th>Groups</th>
<th>Body weight gain (g/day)</th>
<th>Feed intake (g/day)</th>
<th>FER</th>
<th>Liver (g)</th>
<th>Mesenteric AT (g/100 g body wt.)</th>
<th>Epididymal AT (g/100 g body wt.)</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>5.63±0.52</td>
<td>26.20±1.37</td>
<td>0.22±0.03</td>
<td>3.42±0.41</td>
<td>0.97±0.26</td>
<td>2.81±0.13</td>
</tr>
<tr>
<td>N-BA</td>
<td>5.44±0.23</td>
<td>26.54±2.14</td>
<td>0.21±0.04</td>
<td>3.38±0.38</td>
<td>0.91±0.19</td>
<td>1.98±0.29</td>
</tr>
<tr>
<td>HFC</td>
<td>7.22±0.54</td>
<td>22.34±1.80</td>
<td>0.32±0.06</td>
<td>5.17±0.84</td>
<td>1.94±0.22</td>
<td>2.98±0.58</td>
</tr>
<tr>
<td>HFC-BA</td>
<td>6.01±0.37</td>
<td>22.21±1.02</td>
<td>0.27±0.02</td>
<td>4.07±0.70</td>
<td>1.02±0.17</td>
<td>2.31±0.35</td>
</tr>
</tbody>
</table>

1) Groups were as follow: N, normal diet; N-BA, normal diet + B. animalis DY-64 administration; HFC, high-fat/high-cholesterol diet; HFC-BA, high-fat/high-cholesterol diet + B. animalis DY-64 administration.

2) FER (feed efficiency ratio): weight gain (g/day) / feed intake (g/day).

3) AT: adipose tissue.

4) The results are mean±S.E. for eight rats in each group.

5) Values with different superscripts in the same column are significantly different (p<0.05) between groups by Tukey’s test.

Table 3. Effects of B. animalis DY-64 administration on triglyceride and total cholesterol contents in serum of rats fed high-fat/high-cholesterol diet

<table>
<thead>
<tr>
<th>Groups</th>
<th>Triglyceride (mg/dL)</th>
<th>Total cholesterol (mg/dL)</th>
<th>LDL-cholesterol (mg/dL)</th>
<th>HDL-cholesterol (mg/dL)</th>
<th>CRF</th>
<th>AI</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>65.41±5.02</td>
<td>87.97±4.23</td>
<td>64.87±4.29</td>
<td>50.23±4.19</td>
<td>1.75±0.10</td>
<td>0.75±0.04</td>
</tr>
<tr>
<td>N-BA</td>
<td>60.36±7.98</td>
<td>82.34±6.17</td>
<td>59.80±3.79</td>
<td>52.36±5.12</td>
<td>1.57±0.06</td>
<td>0.57±0.05</td>
</tr>
<tr>
<td>HFC</td>
<td>89.14±6.27</td>
<td>109.28±9.36</td>
<td>83.99±5.78</td>
<td>32.29±2.36</td>
<td>3.38±0.06</td>
<td>2.38±0.02</td>
</tr>
<tr>
<td>HFC-BA</td>
<td>72.02±5.74</td>
<td>89.23±7.23</td>
<td>66.42±4.20</td>
<td>42.02±5.01</td>
<td>2.12±0.05</td>
<td>1.12±0.06</td>
</tr>
</tbody>
</table>

1) Groups were as follow: N, normal diet; N-BA, normal diet + B. animalis DY-64 administration; HFC, high-fat/high-cholesterol diet; HFC-BA, high-fat/high-cholesterol diet + B. animalis DY-64 administration.

2) LDL-cholesterol = (total cholesterol – (HDL – cholesterol + triglyceride / 5)).

3) CRF (cardiac risk factor) = total cholesterol / HDL – cholesterol.

4) AI (atherosclerotic index) = (total cholesterol – HDL – cholesterol) / HDL – cholesterol.

5) The results are mean±S.E. for eight rats in each group.

6) Values with different superscripts in the same column are significantly different (p<0.05) between groups by Tukey’s test.
than that of the N group, but it did not differ between the HFC and HFC-BA groups. In the present study, body weight gain of the HFC group was successfully prevented by *B. animalis* DY-64 administration without any alteration of feed intake. FER was higher in the HFC groups (HFC, HFC-BA) than in the N groups (N, N-BA).

**Weights of adipose tissue and liver**

As shown in Table 2, weights of white adipose tissues, including epididymal and mesenteric adipose tissues, were elevated in the HFC groups relative to the N groups. Compared with the HFC group, the HFC-BA group had slightly decreased epididymal adipose tissue weight. In relation to this, Lee *et al.* (2007) has also observed that *Lactobacillus plantarum* PL62 reduced weights of epididymal, inguinal, mesenteric, and perirenal white adipose tissues and significantly reduced body weights in diet-induced obese mice. However, in the N groups (N, NB) with or without *B. animalis* DY-64 administration, weights of adipose tissues were not significantly different among the groups. The effects of diet or *B. animalis* DY-64 administration on adipose tissues weights corresponded with changes in weight gain. These findings were in agreement with previous studies (Lee *et al.*, 2006; Lee *et al.*, 2007).

Liver weights were significantly higher in the HFC groups than in the N groups (Table 2). *B. animalis* DY-64 administration reduced liver weight only in the HFC group. There was no significant effect of *B. animalis* DY-64 administration on liver weight in the N groups.

**Serum leptin contents**

Leptin has been identified as an antiobesity hormone that regulates body weight by controlling food intake and energy expenditure via the hypothalamic-pituitary-gonadal axis (Friedman, 2002). Therefore, leptin may be an important factor in obesity management. Serum leptin contents are shown in Fig. 1. Leptin contents in serum were higher in the HFC groups than in the N groups. However, leptin content of the HFC-BA group was significantly reduced compared with that that of the HFC group. Similar results have been observed in other studies using rats (An *et al.*, 2011), mice (Lee *et al.*, 2006), and humans (Considine *et al.*, 1996). These results suggest that reduction of white adipose tissue and body weights is associated with reduction of leptin. There were no differences in the contents of serum leptin between the N groups.

**Serum lipid contents**

Serum TG, TC, LDL-cholesterol, HDL-cholesterol, atherogenic index (AI), and cardiac risk factor (CRF) in each group are presented in Table 3. Compared with the HFC group, the HFC-BA group showed reduced TG, TC, and LDL-cholesterol contents. The HFC-BA group had showed 19% lower serum TG as well as 18% lower serum TC contents compared to the HFC group. Oral administration of *B. animalis* DY-64 reduced the serum TC level in rats without any pathogenic side effects. However, among the N groups with or without *B. animalis* DY-64 administration, serum TG, TC, LDL-cholesterol, and HDL-cholesterol levels were not significantly different. The concentration of serum LDL-cholesterol declined by 21% in the HFC-BA group compared with the HFC group. Further, there was a significant increase in the AI and CRF of the HFC group compared with the N group, whereas the AI and CRF fell significantly in the HFC-BA group compared with the HFC group. These findings were in agreement with previous studies (Lee *et al.*, 2009; Xie *et al.*, 2011). LDL-cholesterol is the main component of serum cholesterol. Therefore, lowering of the LDL-cholesterol level may be an important factor for reducing serum TC. Reduction of LDL-cholesterol and TG in serum is reported to lower the risk of coronary heart disease (Taylor and Williams, 1998). Our LAB strain attenuated the
increases in serum LDL-cholesterol in rats caused by the HFC group compared to the N group. The present results further show that *B. animalis* DY-64 reduced serum TG, TC, LDL-cholesterol, AI, and CRF in rats fed HFC diet.

**Lipid contents in liver and adipose tissues**

The effects of HFC diet and *B. animalis* DY-64 administration on TG and TC contents in liver and adipose tissues are shown in Tables 4 and 5. Table 4 shows the changes in liver lipids after administration of *B. animalis* DY-64. Similar to serum levels, liver TG and TC levels were significantly reduced by 25 and 35%, respectively, in the HFC-BA group compared to the HFC group. On the other hand, there were no significant differences in liver TG and TC contents among the N groups with or without *B. animalis* DY-64 administration.

TC levels in adipose tissues were not significantly different between the N group and the HFC group (Table 5). TG level in adipose tissue was significantly higher in the HFC groups than in the N groups. However, among the N groups with or without *B. animalis* DY-64 administration, adipose tissue TG and TC levels were not significantly different. However, adipose tissue TG content in the HFC-BA group was significantly reduced compared to the HFC group.

**LPL activity in adipose tissues**

LPL is an enzyme responsible for the hydrolysis of triglycerides from plasma lipoproteins, mainly chylomicron and VLDL, and its activity is influenced by nutritional and hormonal status as well as environmental conditions (Eckel, 1989). Further, LPL is a factor that contributes to the development of obesity (Fried et al., 1989). LPL activity is markedly elevated in adipose tissue of genetically obese rodents (Fried et al., 1989) as well as in obese humans (Ong and Kern, 1989). LPL activities in epididymal and mesenteric adipose tissues were significantly higher.

### Table 4. Effects of *B. animalis* DY-64 administration on triglyceride and total cholesterol contents in liver of rats fed high-fat/high-cholesterol diet

<table>
<thead>
<tr>
<th>Groups</th>
<th>Triglyceride (mg/g, wet weight)</th>
<th>Total cholesterol (mg/g, wet weight)</th>
</tr>
</thead>
<tbody>
<tr>
<td>N</td>
<td>19.24±0.31&lt;sup&gt;a&lt;/sup&gt;</td>
<td>5.64±0.14&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>N-BA</td>
<td>20.13±0.54&lt;sup&gt;a&lt;/sup&gt;</td>
<td>3.99±0.42&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>HFC</td>
<td>31.87±0.45&lt;sup&gt;a&lt;/sup&gt;</td>
<td>9.54±0.28&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>HFC-BA</td>
<td>24.20±0.87&lt;sup&gt;a&lt;/sup&gt;</td>
<td>6.23±0.52&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

Groups were as follow: N, normal diet; N-BA, normal diet + *B. animalis* DY-64 administration; HFC, high-fat/high-cholesterol diet; HFC-BA, high-fat/high-cholesterol diet + *B. animalis* DY-64 administration.

### Table 5. Effects of *B. animalis* DY-64 administration on triglyceride and total cholesterol contents in adipose tissues of rats fed high-fat/high-cholesterol diet

<table>
<thead>
<tr>
<th>Groups</th>
<th>Mesenteric AT</th>
<th>Epididymal AT</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Triglyceride</td>
<td>Total cholesterol</td>
</tr>
<tr>
<td>N</td>
<td>317.51±19.34&lt;sup&gt;ab&lt;/sup&gt;</td>
<td>30.14±2.09&lt;sup&gt;ab&lt;/sup&gt;</td>
</tr>
<tr>
<td>N-BA</td>
<td>328.74±31.29&lt;sup&gt;a&lt;/sup&gt;</td>
<td>32.11±3.48&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>HFC</td>
<td>401.61±21.24&lt;sup&gt;a&lt;/sup&gt;</td>
<td>34.92±2.33&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>HFC-BA</td>
<td>362.11±33.42&lt;sup&gt;b&lt;/sup&gt;</td>
<td>32.64±1.98&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

Groups were as follow: N, normal diet; N-BA, normal diet + *B. animalis* DY-64 administration; HFC, high-fat/high-cholesterol diet; HFC-BA, high-fat/high-cholesterol diet + *B. animalis* DY-64 administration.

<sup>1</sup>Groups were as follow: N, normal diet; N-BA, normal diet + *B. animalis* DY-64 administration; HFC, high-fat/high-cholesterol diet; HFC-BA, high-fat/high-cholesterol diet + *B. animalis* DY-64 administration.

<sup>2</sup>The results are mean±S.E. for eight rats in each group.

<sup>3</sup>Values with different superscripts in the same column are significantly different (p<0.05) among groups by Tukey's test.

<sup>4</sup>The results are mean±S.E. for eight rats in each group.

<sup>5</sup>Groups were as follow: N, normal diet; N-BA, normal diet + *B. animalis* DY-64 administration; HFC, high-fat/high-cholesterol diet; HFC-BA, high-fat/high-cholesterol diet + *B. animalis* DY-64 administration.

<sup>6</sup>Heparin-releasable lipoprotein (HR-LPL) activity was measured in media samples after incubation of epididymal and mesenteric white adipose tissue fragments with 5×10<sup>4</sup> units/L of heparin for 45 min at 24°C.

<sup>7</sup>The results are mean±S.E. for eight rats in each group.

<sup>8</sup>Values with different superscripts in the same column are significantly different (p<0.05) between groups by Tukey's test.
in the HFC group than in the N group (Table 6). LPL is likely to reduce hyperlipidemia induced by consumption of HFC diet. The HFC-BA group had significantly lowered LPL activity in adipose tissues compared to the HFC group. Cruz and Williamson (1992) reported that there is a close correlation between LPL activities in adipose tissue of rats and transportation of triglycerides to adipose tissue, and LPL regulates the accumulation of fat in adipose tissue. Further, LPL activity in mesenteric adipose tissue was lower than that in epididymal adipose tissue.

In the present study, B. animalis DY-64 administration to HFC diet-induced obese rats reduced body weight gain, inhibited adipose tissue accumulation, and reduced LPL in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18, 499-502.


Taylor, G. R. J. and Williams, C. M. (1998) Effects of probi-

(Received 2013.5.6/Revised 2013.10.21/Accepted 2013.10.21)